V1RE1 Inhibitors
V1RE1 inhibitors encompass a range of chemical compounds that directly or indirectly impede the functional activity of V1RE1 through specific signaling pathways. For instance, the PI3K/AKT pathway, known for its role in cellular survival and growth, can be targeted by compounds such as Wortmannin and LY294002, which prevent the activation of AKT and consequently, may reduce the activity of V1RE1 if it is regulated by this pathway. Similarly, MAP kinase pathways like ERK and p38, which are implicated in cell proliferation and stress responses, are inhibited by compounds such as PD98059, U0126, and SB203580. These inhibitors could lead to a decrease in V1RE1 activity if it is downstream of these pathways. Additionally, JNK signaling, which can influence inflammatory responses and apoptosis, is targeted by SP600125, potentially diminishing V1RE1 activity if it operates within this pathway.
Further expanding the arsenal of V1RE1 inhibitors are compoundsthat target various receptor tyrosine kinases and related pathways. Rapamycin, a potent mTOR inhibitor, could suppress V1RE1 activity by intervening in cell growth and proliferation signals that V1RE1 may be involved in. Tyrosine kinase inhibitors, such as PP2, gefitinib, and erlotinib, act on Src family kinases and EGFR signaling, respectively. If V1RE1 is modulated by Src kinase activity or is part of the EGFR pathway, these inhibitors would result in reduced V1RE1 activity. Additionally, multi-targeted kinase inhibitors like sorafenib and sunitinib, which inhibit VEGFRs and PDGFRs, could similarly lead to decreased activity of V1RE1 if it is associated with these receptor-mediated signaling events. Collectively, these compounds demonstrate the diverse mechanisms through which V1RE1 can be inhibited, pointing to the intricate network of pathways that converge on the regulation of this protein's activity. Each inhibitor works through a specific biochemical interaction, enabling precise modulation of V1RE1 and its associated cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin can prevent the downstream activation of AKT, which is crucial for many signaling pathways, including those that V1RE1 may be involved in, leading to decreased functional activity of V1RE1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor. Similar to wortmannin, it blocks the PI3K/AKT pathway, reducing the phosphorylation and subsequent activation of downstream targets that could include proteins like V1RE1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which in turn inhibits the extracellular signal-regulated kinase (ERK) pathway. This could lead to reduced activity of V1RE1 if it is downstream of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that impedes the ERK pathway. By blocking MEK, U0126 can indirectly decrease the functional activity of V1RE1 if it is regulated by the MEK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in response to stress and cytokines. If V1RE1 activity is modulated by the p38 MAPK pathway, then inhibition by SB203580 could lead to a decrease in V1RE1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), potentially impacting proteins regulated by the JNK signaling pathway. If V1RE1 is such a protein, its activity would be decreased by SP600125. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which affects cell growth and proliferation. Inhibition of mTOR could lead to a decrease in V1RE1 activity if it is part of or regulated by this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinase activity can regulate various cellular processes, and inhibition by PP2 could reduce V1RE1 activity if it is associated with Src signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By blocking EGFR signaling, it can lead to reduced activity of downstream proteins like V1RE1, if V1RE1 is involved in EGFR signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib also inhibits EGFR tyrosine kinase activity. Similar to gefitinib, it can decrease the activity of proteins involved in the EGFR pathway, potentially including V1RE1. | ||||||